Tirzepatide
A dual GIP/GLP-1 agonist that changed expectations for medical weight loss and became one of the most recognizable metabolic peptide drugs.
What It Is
Tirzepatide is a once-weekly peptide drug that activates both GIP and GLP-1 receptors. It is marketed in the U.S. as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, with Zepbound also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.
What People Notice Most
Obesity trials produced average losses well beyond older anti-obesity medications.
Strong humanUsers commonly describe less hunger, earlier fullness and reduced food noise.
Strong human / patient reportedPowerful A1C lowering is central to its diabetes indication.
Strong humanWeight-loss-mediated improvement in OSA led to an FDA-approved indication.
Strong humanWhy It Became A Benchmark
Tirzepatide made “dual agonist” a mainstream concept. For many people it is the comparison point for newer metabolic compounds: if a new peptide is being developed for obesity, the obvious question is whether it can match or exceed tirzepatide’s combination of appetite control, glycemic effects and weight loss.
GIP + GLP-1 Signaling
GLP-1 receptor activation slows gastric emptying, increases glucose-dependent insulin secretion and supports satiety. GIP signaling adds another incretin pathway affecting insulin secretion and energy balance. Tirzepatide combines those activities in one molecule.
What Human Trials Show
The SURMOUNT obesity program demonstrated substantial mean weight loss across studied maintenance doses, with higher doses generally producing larger effects. The SURPASS program established robust glycemic control in type 2 diabetes. Additional trials supported Zepbound’s OSA indication.
Established Drug, Real Tradeoffs
Common adverse effects are gastrointestinal, especially nausea, diarrhea, vomiting and constipation. FDA labeling includes contraindications and warnings, including the boxed warning regarding thyroid C-cell tumors observed in rodents.
Labeled Titration
Approved products use once-weekly subcutaneous dosing with a low starting dose followed by stepwise increases to reduce gastrointestinal intolerance. Exact maintenance choices depend on the indication, response, tolerability and current product labeling.